[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PsychedVantage Avatar @PsychedVantage Psychedelic Vantage

Psychedelic Vantage posts on X about $atai, $cmps, $ghrs, $cybn the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks finance exchanges

Social topic influence $atai, $cmps, $ghrs, $cybn, $mnmd, stocks, investment, imo, $neup, $drug

Top assets mentioned ATAI Life Sciences (ATAI) Sarepta Therapeutics, Inc. (SRPT)

Top Social Posts #

Top posts by engagements in the last XX hours

"Had a very cautious stance until I saw its valuation become out of touch with reality (IMO) and purchased a large amount of shares in $XXXX range. Much more to my investment thesis in $CMPS. Very high risk/high reward play. Unfortunately rn I am exhausted but will try to give you a more complete answer later. -Jake"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-23 18:51:13 UTC 1350 followers, XXX engagements

"I have cash sitting on the sidelines to buy names I view as being undervalued in the neuropsychiatry space. Tickers I am looking at include $ATAI $CYBN $VTGN $ANRO $DRUG $NEUP. I am already overweight $ATAI but the news-flow I am anticipating in the coming months makes me inclined to buy more if the market continues to overreact to RL-007 miss (a drug I and many others were not expecting to meet its primary endpoint in CIAS). Along with several clinical trial readouts with de-risked psychedelic assets anticipated in the coming months for $ATAI an announcement of breakthrough therapy"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 22:19:34 UTC 1358 followers, 5643 engagements

"On the buying side ARK also picked up 489751 shares of ATAI LIFE SCIENCES NV (NASDAQ: $ATAI) through its $ARKG ETF valued at $1748411"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-29 00:23:47 UTC 1358 followers, 1406 engagements

"@InvestinginCan1 Would love to have you on the channel @InvestinginCan1 to share more with our audience about $PSIL. Lmk -Jake"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 23:01:17 UTC 1352 followers, XXX engagements

"Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia $ATAI"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 20:13:05 UTC 1358 followers, 5248 engagements

"Great question. While the answer can be complex if the data meet endpoints and the benefit-risk profile is favorable the FDA will approve these treatment in my opinion. I am confident that many of the current psychedelic drug developers have learned from the missteps made by Lykos. Most notably I am confident that they are properly collecting the safety data the agency expects to see enrolling mostly psychedelic-naive participants demonstrating dose-response relationships and conducting much larger studies. The Lykos trials were unusually small for a Phase X program in psychiatry. Many of"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-26 15:47:25 UTC 1350 followers, XXX engagements

"Current members of the Association for Prescription Psychedelics (@PsychedelicsRX) Mission statement: To educate and advocate for the development and accessibility of safe and effective prescription psychedelic medicines for patients"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-16 23:28:32 UTC 1350 followers, 1253 engagements

"Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a while you know these holdings have changed quite a bit over time. What does your breakdown look like Jake $CMPS $MNMD $CYBN $ATAI $GHRS"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-01 21:03:37 UTC 1350 followers, 7096 engagements

"Compass Pathways to Announce Second Quarter Financial Results on July XX 2025 $CMPS"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-22 11:07:22 UTC 1350 followers, 1199 engagements

"$GHRS data was indeed very impressive. Day X endpoint and aggressive re-treatment criteria in open-label (credit to GH for this btw) make it very hard to compare with BPL-003 data which had a much different trial design. $ATAI was also looking at a harder to treat population based off of baseline MADRS scores length of current depressive episodes and number of lifetime depressive episodes etc. I am a big fan of both $ATAI and $GHRS. -Jake"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-28 16:24:12 UTC 1356 followers, XXX engagements

"Looking forward to hearing @MatteisPauls take here on $GHRS clinical hold. $GHRS $ATAI"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 15:23:22 UTC 1355 followers, XXX engagements

"True or False: Psychedelic drug development company stocks are shifting from meme stocks to serious plays as mid/late-stage data show good safety & efficacy with intermittent dosing in hard-to-treat mental health conditions. $CMPS $MNMD $CYBN $ATAI $GHRS"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-10 23:16:48 UTC 1350 followers, 1419 engagements

"MindMed to Report Second Quarter 2025 Financial Results on July XX 2025 $MNMD"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-24 11:01:25 UTC 1350 followers, XXX engagements

"It will be interesting to compare data from both phase X programs in the future. GH-001 phase 2b trial design made it almost impossible to compare with BPL-003 data. Credit to $ATAI for looking at durability in a blinded fashion out to X months after a single treatment and credit to $GHRS for exploring re-treatment out to X months in a phase 2b trial (first to do so in a phase X in this space). I don't think day X endpoint will cut it for phase X though with GH-001. -Jake"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 16:00:45 UTC 1354 followers, XXX engagements

"@flobrand @LarsWilde Appreciate the breadown @flobrand @LarsWilde Would love to hear your thoughts on how pharma may be viewing the IP landscape with first and second generation psychedelics. -Jake"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-29 23:02:40 UTC 1358 followers, XXX engagements

"RBC Capital Markets Global Healthcare Conference Conversation with @NathKabir $CMPS"
@PsychedVantage Avatar @PsychedVantage on X 2025-07-25 13:16:59 UTC 1350 followers, XXX engagements